Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Qualigen Therapeutics Inc (QLGN) USD0.001

Sell:$1.42 Buy:$1.46 Change: $0.03 (2.08%)
Market closed |  Prices as at close on 16 September 2021 | Switch to live prices |
Change: $0.03 (2.08%)
Market closed |  Prices as at close on 16 September 2021 | Switch to live prices |
Change: $0.03 (2.08%)
Market closed |  Prices as at close on 16 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Qualigen Therapeutics, Inc., formerly Ritter Pharmaceuticals, Inc., is a biotechnology company. The Company is focused on the development and commercialization of therapeutic products for the treatment of cancer and infectious diseases, as well as development of its FastPack diagnostic platform. Its pipeline includes AS1411, Aptamer Linked Anti Nucleolin (ALAN), Aptamer Linked Anti Nucleolin - Contrast Enhancement (ALAN-CE), Aptamer Linked Anti Nucleolin - Radiation Enhancement (ALAN-RE), Selective Target Antigen Removal System (STARS) and RAS-F. The FastPack System is an immunoassay testing system, which consists of the FastPack Analyzer and the FastPack test pouch, a single-use, disposable, foil packet which includes the FastPack reagent chemistry. The Company’s subsidiary is Qualigen, Inc.

Contact details

1880 Century Park E Ste 1000
United States
+1 (310) 2031000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$39.73 million
Shares in issue:
29.00 million
United States
US dollar

Key personnel

  • Michael Poirier
    Chairman of the Board, President, Chief Executive Officer
  • Christopher Lotz
    Chief Financial Officer, Vice President - Finance
  • Shishir Sinha
    Chief Operating Officer, Vice President
  • Amy Broidrick
    Executive Vice President, Chief Strategy Officer, Director
  • Tariq Arshad
    Senior Vice President, Chief Medical Officer
  • Wajdi Abdul-Ahad
    Chief Scientific Officer, Vice President - Research and Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.